Aspirin can be life saving in patients with acute coronary events, but its use in patients with cancer, particularly in those with thrombocytopenia, is often avoided, presumably for fear of hemorrhagic complications. In this retrospective review of 70 patients who sustained an acute coronary event while at MD Anderson Cancer Center, over a one year period, aspirin treatment was associated with significantly better survival and this was true for the subgroup with normal platelet counts and the group with thrombocytopenia. Furthermore, there was no observed hemorrhagic complication in the aspirin treated patients.Source:
Starkiss MG, et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007;109:621-627.